Literature DB >> 23689116

In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression.

Jiro Shimazaki1, Yoshihisa Goto, Kiyotaka Nishida, Takanobu Tabuchi, Gyo Motohashi, Hideyuki Ubukata, Takafumi Tabuchi.   

Abstract

OBJECTIVE: To investigate the clinical significance of the serum inflammatory cytokines and the blood granulocytes/lymphocytes (G/L) ratio in patients with colorectal cancer.
METHODS: Forty-six patients underwent surgery for colorectal cancer. The G/L ratio and serum inflammatory cytokines including interleukin (IL)-1β, IL-6, IL-8, tumour necrosis factor-α (TNF-α), granulocyte colony-stimulating factor and macrophage colony-stimulating factor (M-CSF) were measured before surgery and correlated with the Tumour Node Metastasis classification and overall survival.
RESULTS: Serum IL-6 in T3-4, N1-2, M1 cases and cancer stages III-IV sub-groups was significantly higher than in Tis-2, N0, M0 and cancer stages 0-II sub-groups. The G/L ratio, serum M-CSF and TNF-α in T3-4 cases were significantly higher than in Tis-2 cases. Furthermore, the G/L ratio and serum IL-6 showed a significant inverse correlation with the overall survival, while the G/L ratio showed a significant positive correlation with serum IL-6, TNF-α and M-CSF. Multivariate analysis showed that the serum IL-6 level and G/L ratio were independent risk factors for poor prognosis.
CONCLUSIONS: In this investigation, a pre-operative high level of serum IL-6 and the G/L ratio appeared to be significant predictive factors for cancer progression and poor prognosis. Accordingly, these variables might be clinically relevant biomarkers in patients with colorectal cancer.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689116     DOI: 10.1159/000350836

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  22 in total

1.  Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.

Authors:  Vincenzo Formica; Jessica Luccchetti; David Cunningham; Elizabeth C Smyth; Patrizia Ferroni; Antonella Nardecchia; Manfredi Tesauro; Vittore Cereda; Fiorella Guadagni; Mario Roselli
Journal:  Med Oncol       Date:  2014-08-23       Impact factor: 3.064

2.  Inflammatory cytokines, appetite-regulating hormones, and energy metabolism in patients with gastrointestinal cancer.

Authors:  Ayaka Shinsyu; Shigeki Bamba; Mika Kurihara; Hiroshi Matsumoto; Ayano Sonoda; Osamu Inatomi; Akira Andoh; Katsushi Takebayashi; Masatsugu Kojima; Hiroya Iida; Masaji Tani; Masaya Sasaki
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967

3.  Pre-treatment neutrophil to lymphocyte ratio as a predictive marker for pathological response to preoperative chemoradiotherapy in pancreatic cancer.

Authors:  Shinichiro Hasegawa; Hidetoshi Eguchi; Akira Tomokuni; Yoshito Tomimaru; Tadafumi Asaoka; Hiroshi Wada; Naoki Hama; Koichi Kawamoto; Shogo Kobayashi; Shigeru Marubashi; Masamitsu Konnno; Hideshi Ishii; Masaki Mori; Yuichiro Doki; Hiroaki Nagano
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

4.  Serum cytokine profile as a potential prognostic tool in colorectal cancer patients - one center study.

Authors:  Paulina Czajka-Francuz; Tomasz Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Marcin Fajkis; Bożena Szymczak; Maciej Kozaczka; Krzysztof Piotr Malinowski; Wojciech Zasada; Jerzy Wojnar; Jerzy Chudek
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-21

Review 5.  Role of innate immunity in chemotherapy-induced peripheral neuropathy.

Authors:  Megan L Uhelski; Yan Li; Miriam M Fonseca; E Alfonso Romero-Snadoval; Patrick M Dougherty
Journal:  Neurosci Lett       Date:  2021-05-04       Impact factor: 3.197

6.  Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.

Authors:  Z-Y Chen; K Raghav; C H Lieu; Z-Q Jiang; C Eng; J-N Vauthey; G J Chang; W Qiao; J Morris; D Hong; P Hoff; H Tran; D G Menter; J Heymach; M Overman; S Kopetz
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

7.  Prognostic and clinicopathological significance of serum interleukin-6 expression in colorectal cancer: a systematic review and meta-analysis.

Authors:  Zhen Wang; Pin Wu; Dang Wu; Zhigang Zhang; Guoming Hu; Shuai Zhao; Yucheng Lai; Jian Huang
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

8.  Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis.

Authors:  Wenjie Xia; Wuzhen Chen; Zhigang Zhang; Dang Wu; Pin Wu; Zhigang Chen; Chao Li; Jian Huang
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

9.  Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.

Authors:  Xinwei Hua; Mario Kratz; Rachel C Malen; James Y Dai; Sara Lindström; Yingye Zheng; Polly A Newcomb
Journal:  Br J Cancer       Date:  2021-07-06       Impact factor: 9.075

Review 10.  Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3.

Authors:  Akio Tomoda; Keisuke Miyazawa; Takafumi Tabuchi
Journal:  Int J Mol Sci       Date:  2013-08-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.